1. Home
  2. DAWN

DAWN

Day One Biopharmaceuticals Inc.

Logo Day One Biopharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 10:31am EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Founded: 2018 Country:
United States
United States
Employees: 155 City: BRISBANE
Market Cap: 1.3B IPO Year: 2021
Target Price: $35.33 AVG Volume (30 days): 675.9K
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.37 EPS Growth: N/A
52 Week Low/High: $9.67 - $17.85 Next Earning Date: 05-03-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 468.62%

Share on Social Networks:

Stock Insider Trading Activity of Day One Biopharmaceuticals Inc. (DAWN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Blackman Samuel C. DAWN HEAD OF R&D Mar 11 '24 Sell $15.24 30,000 $457,314.00 1,194,662 SEC Form 4
Blackman Samuel C. DAWN HEAD OF R&D Feb 27 '24 Sell $16.11 20,000 $322,166.00 1,224,662 SEC Form 4
Dubow Adam DAWN General Counsel Nov 15 '23 Sell $11.69 5,313 $62,108.97 11,428 SEC Form 4
Blackman Samuel C. DAWN Head of Research and Developme Nov 15 '23 Sell $11.69 709 $8,288.21 1,238,234 SEC Form 4
Bender Jeremy DAWN Chief Executive Officer Nov 15 '23 Sell $11.69 3,107 $36,320.83 709,429 SEC Form 4